Literature DB >> 8377971

The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus.

I B Van den Veyver1, K J Moise, C N Ou, R J Carpenter.   

Abstract

OBJECTIVE: To determine the effects of gestational age and fetal serum indomethacin levels on constriction of the ductus arteriosus after maternal indomethacin administration.
METHODS: Twenty-five pregnant Rh-sensitized patients were given a 50-mg oral dose of indomethacin 6 hours before fetal serum indomethacin levels were determined at the time of 50 diagnostic or therapeutic funipunctures. The ductus arteriosus was evaluated with Doppler ultrasound immediately before 40 of the procedures. Constriction of the ductus arteriosus was defined as a peak diastolic flow greater than 35 cm/second. Least-squares regression and multiple regression were used for statistical analysis.
RESULTS: The peak diastolic velocity of the fetal ductus arteriosus after maternal indomethacin ingestion was constant at 25 cm/second before 27 weeks, increased between 27-30 weeks to a mean of 39 cm/second, and was stable thereafter (R2 = 0.35; P < .05). There was no significant correlation between constriction of the ductus and fetal serum indomethacin levels (P = .17).
CONCLUSIONS: The constrictive effect of maternal indomethacin ingestion on the fetal ductus arteriosus begins as early as 27 weeks' gestation. Constriction of the ductus arteriosus is independent of fetal serum indomethacin levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8377971

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

Review 1.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice.

Authors:  Jeff Reese; Judy D Anderson; Naoko Brown; Christine Roman; Ronald I Clyman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-07-20       Impact factor: 3.619

Review 3.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

Review 4.  Optimisation of antirheumatic drug treatment in pregnancy.

Authors:  M Ostesen
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

Review 5.  Comparative tolerability of pharmacological treatments for patent ductus arteriosus.

Authors:  C Hammerman; M Kaplan
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

6.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

7.  Are complicated monochorionic twins more susceptible to indomethacin-induced fetal ductal constriction? Two cases of laser surgery for Twin-Twin Transfusion syndrome.

Authors:  Hakan Erenel; Mehmet Fatih Karslı; Sevim Özge Korkmaz; Cihat Şen
Journal:  Turk J Obstet Gynecol       Date:  2018-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.